# A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

> **NCT04396821** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Suzhou Transcenta Therapeutics Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Advanced Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** TST001
- **DRUG:** Nivolumab Injection [Opdivo]
- **DRUG:** mFOLFOX6
- **DRUG:** Gemcitabine
- **DRUG:** Albumin-Bound Paclitaxel

## Key facts

- **NCT ID:** NCT04396821
- **Lead sponsor:** Suzhou Transcenta Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-28
- **Primary completion:** 2026-05-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04396821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04396821, "A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04396821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*